Arterial Spin-Labeling Evaluation of Cerebrovascular Reactivity to Acetazolamide in Healthy Subjects

References

1. 1.↵
   1. Hendrikse J,
   2. Petersen ET,
   3. Golay X

   . Vascular disorders: insights from arterial spin labeling. Neuroimaging Clin North Am 2012;22:259–69

   CrossRef
2. 2.↵
   1. Pollock JM,
   2. Tan H,
   3. Kraft RA,
   4. et al

   . Arterial spin-labeled MR perfusion imaging: clinical applications. Magn Reson Imaging Clin North Am 2009;17:315–38

   CrossRef
3. 3.↵
   1. Dai W,
   2. Garcia D,
   3. de Bazelaire C,
   4. et al

   . Continuous flow-driven inversion for arterial spin labeling using pulsed radio frequency and gradient fields. Magn Reson Med 2008;60:1488–97

   CrossRefPubMedWeb of Science
4. 4.↵
   1. Powers WJ,
   2. Raichle ME

   . Positron emission tomography and its application to the study of cerebrovascular disease in man. Stroke 1985;16:361–76

   FREE Full Text
5. 5.↵
   1. Hirano T,
   2. Minematsu K,
   3. Hasegawa Y,
   4. et al

   . Acetazolamide reactivity on ¹²³I-IMP single photon emission computed tomography in patients with major cerebral artery occlusive disease: correlation with positron emission tomography parameters. J Cereb Blood Flow Metab 1994;14:763–70

   CrossRefPubMedWeb of Science
6. 6.↵
   1. Yudd AP,
   2. Van Heertum RL,
   3. Masdeu JC

   . Interventions and functional brain imaging. Semin Nucl Med 1991;21:153–58

   CrossRefPubMed
7. 7.↵
   1. Uchihashi Y,
   2. Hosoda K,
   3. Zimine I,
   4. et al

   . Clinical application of arterial spin-labeling MR imaging in patients with carotid stenosis: quantitative comparative study with single-photon emission CT. AJNR Am J Neuroradiol 2011;32:1545–51

   Abstract/FREE Full Text
8. 8.↵
   1. Zaitsu Y,
   2. Kudo K,
   3. Terae S,
   4. et al

   . Mapping of cerebral oxygen extraction fraction changes with susceptibility-weighted phase imaging. Radiology 2011;261:930–36

   CrossRefPubMed
9. 9.↵
   1. Bokkers RP,
   2. van Osch MJ,
   3. Klijn CJ,
   4. et al

   . Cerebrovascular reactivity within perfusion territories in patients with an internal carotid artery occlusion. J Neurol Neurosurg Psychiatry 2011;82:1011–16

   Abstract/FREE Full Text
10. 10.↵
    1. Bokkers RP,
    2. van Osch MJ,
    3. van der Worp HB,
    4. et al

    . Symptomatic carotid artery stenosis: impairment of cerebral autoregulation measured at the brain tissue level with arterial spin-labeling MR imaging. Radiology 2010;256:201–08

    CrossRefPubMedWeb of Science
11. 11.↵
    1. Yen YF,
    2. Field AS,
    3. Martin EM,
    4. et al

    . Test-retest reproducibility of quantitative CBF measurements using FAIR perfusion MRI and acetazolamide challenge. Magn Reson Med 2002;47:921–28

    CrossRefPubMedWeb of Science
12. 12.↵
    1. Detre JA,
    2. Samuels OB,
    3. Alsop DC,
    4. et al

    . Noninvasive magnetic resonance imaging evaluation of cerebral blood flow with acetazolamide challenge in patients with cerebrovascular stenosis. J Magn Reson Imaging 1999;10:870–75

    CrossRefPubMedWeb of Science
13. 13.↵
    1. Wu WC,
    2. St Lawrence KS,
    3. Licht DJ,
    4. et al

    . Quantification issues in arterial spin labeling perfusion magnetic resonance imaging. Top Magn Reson Imaging 2010;21:65–73

    CrossRefPubMed
14. 14.↵
    1. Xu G,
    2. Rowley HA,
    3. Wu G,
    4. et al

    . Reliability and precision of pseudo-continuous arterial spin labeling perfusion MRI on 3.0 T and comparison with ¹⁵O-water PET in elderly subjects at risk for Alzheimer's disease. NMR Biomed 2010;23:286–93

    PubMedWeb of Science
15. 15.↵
    1. Takeuchi R,
    2. Yonekura Y,
    3. Matsuda H,
    4. et al

    . Usefulness of a three-dimensional stereotaxic ROI template on anatomically standardised ^99mTc-ECD SPET. Eur J Nucl Med Mol Imaging 2002;29:331–41

    CrossRefPubMed
16. 16.↵
    1. Petersen ET,
    2. Zimine I,
    3. Ho YC,
    4. et al

    . Non-invasive measurement of perfusion: a critical review of arterial spin labelling techniques. Br J Radiol 2006;79:688–701

    Abstract/FREE Full Text
17. 17.↵
    1. Dahl A,
    2. Russell D,
    3. Rootwelt K,
    4. et al

    . Cerebral vasoreactivity assessed with transcranial Doppler and regional cerebral blood flow measurements: dose, serum concentration, and time course of the response to acetazolamide. Stroke 1995;26:2302–06

    Abstract/FREE Full Text
18. 18.↵
    1. Hauge A,
    2. Nicolaysen G,
    3. Thoresen M

    . Acute effects of acetazolamide on cerebral blood flow in man. Acta Physiol Scand 1983;117:233–39

    CrossRefPubMedWeb of Science
19. 19.↵
    1. Hartkamp NS,
    2. Hendrikse J,
    3. van der Worp HB,
    4. et al

    . Time course of vascular reactivity using repeated phase-contrast MR angiography in patients with carotid artery stenosis. Stroke 2012;43:553–56

    Abstract/FREE Full Text
20. 20.↵
    1. Inoue Y,
    2. Momose T,
    3. Machida K,
    4. et al

    . An approach to cerebral vasodilatory capacity in unilateral and bilateral cerebrovascular diseases using radiolabeled human serum albumin. Clin Nucl Med 1995;20:340–45

    CrossRefPubMed
21. 21.↵
    1. Sorteberg W,
    2. Lindegaard KF,
    3. Rootwelt K,
    4. et al

    . Effect of acetazolamide on cerebral artery blood velocity and regional cerebral blood flow in normal subjects. Acta Neurochir (Wien) 1989;97:139–45

    CrossRefPubMed
22. 22.↵
    1. Bonte FJ,
    2. Devous MD,
    3. Reisch JS

    . The effect of acetazolamide on regional cerebral blood flow in normal human subjects as measured by single-photon emission computed tomography. Invest Radiol 1988;23:564–68

    CrossRefPubMedWeb of Science
23. 23.↵
    1. Vorstrup S,
    2. Brun B,
    3. Lassen NA

    . Evaluation of the cerebral vasodilatory capacity by the acetazolamide test before EC-IC bypass surgery in patients with occlusion of the internal carotid artery. Stroke 1986;17:1291–98

    Abstract/FREE Full Text
24. 24.↵
    1. Endo H,
    2. Inoue T,
    3. Ogasawara K,
    4. et al

    . Quantitative assessment of cerebral hemodynamics using perfusion-weighted MRI in patients with major cerebral artery occlusive disease: comparison with positron emission tomography. Stroke 2006;37:388–92

    Abstract/FREE Full Text
25. 25.↵
    1. Okazawa H,
    2. Yamauchi H,
    3. Sugimoto K,
    4. et al

    . Effects of acetazolamide on cerebral blood flow, blood volume, and oxygen metabolism: a positron emission tomography study with healthy volunteers. J Cereb Blood Flow Metab 2001;21:1472–79

    CrossRefPubMedWeb of Science
26. 26.↵
    1. MacIntosh BJ,
    2. Filippini N,
    3. Chappell MA,
    4. et al

    . Assessment of arterial arrival times derived from multiple inversion time pulsed arterial spin labeling MRI. Magn Reson Med 2010;63:641–47

    CrossRefPubMed
27. 27.↵
    1. Chen Y,
    2. Wang DJ,
    3. Detre JA

    . Test-retest reliability of arterial spin labeling with common labeling strategies. J Magn Reson Imaging 2011;33:940–49

    CrossRefPubMed
28. 28.↵
    1. Pfefferbaum A,
    2. Chanraud S,
    3. Pitel AL,
    4. et al

    . Volumetric cerebral perfusion imaging in healthy adults: regional distribution, laterality, and repeatability of pulsed continuous arterial spin labeling (PCASL). Psychiatry Res 2010;182:266–73

    CrossRefPubMedWeb of Science
29. 29.↵
    1. Wu WC,
    2. Jiang SF,
    3. Yang SC,
    4. et al

    . Pseudocontinuous arterial spin labeling perfusion magnetic resonance imaging: a normative study of reproducibility in the human brain. Neuroimage 2011;56:1244–50

    CrossRefPubMed
30. 30.↵
    1. Jahng GH,
    2. Song E,
    3. Zhu XP,
    4. et al

    . Human brain: reliability and reproducibility of pulsed arterial spin-labeling perfusion MR imaging. Radiology 2005;234:909–16

    CrossRefPubMed